The Economics of Reproducibility in Preclinical Research

By L. Freedman, Iain M. Cockburn, Timothy S. Simcoe. PLoS Biology, 2015

949 citations recorded by the source corpus.

Low reproducibility rates within life science research undermine cumulative knowledge production and contribute to both delays and costs of therapeutic drug development. An analysis of past studies indicates that the cumulative (total) prevalence of irreproducible preclinical research exceeds 50%, resulting in approximately US$28,000,000,000 (US$28B)/year spent on preclinical research that is not reproducible—in the United States alone. We outline a framework for solutions and a plan for long-term improvements in reproducibility rates that will help to accelerate the discovery of life-saving therapies and cures.

Subfields: Biomedical Engineering, Biophysics, Immunology

View Paper: https://www.semanticscholar.org/paper/f0fa01e5b242680519b99233082b5afdb9c205cb

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. Nan Zhou
2. Jinku Bao

Citations in the corpus

• FerrDb: a manually curated resource for regulators and markers of ferroptosis and ferroptosis-disease associations (2020, background): “We acknowledge that this assumption may introduce some errors because unreliable scientific claims might exist in original studies, especially in life sciences research which is beset by low reproducibility rates (16).”